(pyrrolidin-2-yl) methanol hydrochloride | 41325-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (pyrrolidin-2-yl) methanol hydrochloride
• 英文别名: 2-hydroxymethylpyrrolidine hydrochloride；2-Pyrrolidinemethanol hydrochloride；pyrrolidin-2-ylmethanol;hydrochloride
• CAS: 41325-79-5
• 化学式: C₅H₁₁NO*ClH
• 分子量: 137.609
• InChiKey: FWXXCGIUQGFYIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (pyrrolidin-2-yl) methanol hydrochloride 、 7-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-N-[2-chloro-3-[2-chloro-3-(5-formyl-6-methoxypyrazin-2-yl)phenyl]phenyl]-4-methyl-6,8-dihydro-5H-1,7-naphthyridine-2-carboxamide 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 7-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-N-[2-chloro-3-[2-chloro-3-[5-[[2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-6-methoxypyrazin-2-yl]phenyl]phenyl]-4-methyl-6,8-dihydro-5H-1,7-naphthyridine-2-carboxamide
  参考文献：
  名称：

  COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF

  摘要：

  一种双芳基化合物。具体公开的是由式(I)表示的化合物及其药学上可接受的盐。

  公开号：

  EP4043461A1

文献信息

• CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
  申请人：FLX Bio, Inc.

  公开号：US20180072743A1

  公开（公告）日：2018-03-15

  Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

  披露的内容包括但不限于，用于调节趋化因子受体活性的化合物及其使用方法。
• DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150152096A1

  公开（公告）日：2015-06-04

  Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

  本文提供了二氢嘧啶化合物及其药物应用，特别用于治疗和预防HBV疾病。具体来说，本文提供了具有化学式（I）或（Ia）的化合物，或其对映体、二对映异构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐，其中化学式的变量如规范中所定义。本文还提供了利用具有化学式（I）或（Ia）的化合物，或其对映体、二对映异构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐来治疗和预防HBV疾病。
• [EN] DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS<br/>[FR] COMPOSÉS DE DIHYDROPYRIMIDINE ET LEUR APPLICATION DANS DES PRODUITS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014029193A1

  公开（公告）日：2014-02-27

  Provided herein are dihydropyrimidine compounds and their pharmaceutical　applications, especially for use in treating and preventing HBV diseases. Specifically,provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

  本文提供了二氢嘧啶化合物及其药物应用，特别是用于治疗和预防HBV疾病。具体而言，本文提供了具有化学式(I)或(Ia)的化合物，或其对映体、对二构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐，其中化合物的变量如规范中所定义。本文还提供了使用具有化学式(I)或(Ia)的化合物，或其对映体、对二构体、互变异构体、水合物、溶剂合物或其药学上可接受的盐用于治疗和预防HBV疾病。
• COMPOUNDS AND USE FOR TREATING CANCER
  申请人：GLIONOVA AB

  公开号：US20160214958A1

  公开（公告）日：2016-07-28

  The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

  本发明涉及某些2,4-二取代喹啉衍生物及其治疗方法，以及包含该化合物的制药组合物。更具体地说，本发明涉及某些2,4-二取代喹啉衍生物或包含该化合物的制药组合物，用于治疗由过度活跃的Ras和/或Rac或信号通路所特征的癌症。
• Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
  申请人：Moriya Minoru

  公开号：US20050222161A1

  公开（公告）日：2005-10-06

  This invention relates to a benzimidazole derivative of the general formula [I] [wherein B 1 , B 2 , and B 3 represent hydrogen atom or lower alkyl; R 1 and R 2 are same or different and represent lower alkyl, etc.; R 3 and R 4 represent hydrogen atom, etc.; W represents a 3 to 8-membered aromatic or alphatic heterocycle, etc.; and Ar represents a substituted or unsubstituted aromatic heterocycle, etc.] This compound functions as an antagonist to melanin-concentrating hormone receptor and is useful as a drug for central diseases, circulatory diseases and metabolic diseases.

  本发明涉及一种苯并咪唑衍生物，其一般式为[I] [其中B1，B2和B3代表氢原子或低碳基; R1和R2相同或不同，代表低碳基等; R3和R4代表氢原子等; W代表3至8个成员的芳香或脂肪族杂环等; Ar代表取代或未取代的芳香族杂环等] 该化合物作为黑色素浓缩激素受体的拮抗剂，并可用作中枢疾病、循环系统疾病和代谢性疾病的药物。